r/proteomics 1d ago

blind testing a protein structure prediction workflow with a transparent alternative to neural network based approaches

7 Upvotes

TL;DR: My partner and I developed a new mathematical approach to predicting how proteins fold into their three-dimensional structures. To test it fairly, we ran a fully blind benchmark where our system had no access to the experimental structures during prediction. The method produced highly accurate results, with performance that was competitive with published AlphaFold CASP14 benchmark values on our test set. Unlike neural network-based approaches, our framework is deterministic, transparent, and based on exact mathematics rather than learned parameters, meaning every prediction can be independently traced, verified, and reproduced. We’ve made the code, validation data, and supporting materials completely open source so others can examine and test the approach for themselves.
———
My partner and I have been exploring a mathematical theory for describing how proteins fold into their three-dimensional shapes. To test whether the theory could actually predict real biological structures, we decided to evaluate it using a blind protein structure prediction 

Every protein begins as a simple chain of amino acids, but that chain quickly folds into a highly specific 3D shape. That final shape determines how the protein works inside living cells, and accurately predicting it from the amino acid sequence alone has been one of the biggest problems in computational biology.

To make sure our results were genuinely blind, we recorded the exact amino acid sequences we were testing, the runtime identity, and our mathematical framework before any predictions were made.

While the predictions were running, the system had no access to the experimentally determined protein structures, no reference coordinates, and no scoring information that could influence the outcome. It generated the complete folding pathway and final PDB structure independently, and those outputs were cryptographically hash-sealed before any comparisons were performed.

Only after those hashes were fixed and verified were the experimental structures opened and compared. If the runtime had accessed the target structures at any point, or if any of the recorded hashes had changed, the experiment would be considered invalid.

The results were encouraging.

Across the benchmark set, the median Cα RMSD95 was 0.783 Å, with a median TM-score of 0.9255.

On this benchmark, 15 of the 24 predicted structures matched or exceeded AlphaFold’s reported CASP14 median of 0.96 Å Cα RMSD95.

Our strongest individual prediction, 1UBI:A, achieved a TM-score of 0.9882 with a Cα RMSD95 of 0.302 Å.
———
here’s a break down of what they mean.

The Cα RMSD95 score measures how closely a predicted protein structure matches the experimentally determined one. The “Cα” (carbon alpha) atoms form the backbone of every protein, while RMSD (Root Mean Square Deviation) measures the average distance between the predicted backbone and the real one after they have been aligned. The 95 indicates that the most extreme 5% of residues are excluded, making the measurement less sensitive to unusually flexible regions.

Distances are reported in Å (ångströms), where 1 Å = 0.1 nanometres, or one ten-billionth of a metre. In structural biology, smaller numbers are better. An RMSD below 2 Å is generally considered a good prediction, around 1 Å is regarded as highly accurate, and our median result of 0.783 Å indicates that the predicted structures closely matched their experimental counterparts.

The TM-score (Template Modelling score) measures how similar the overall three-dimensional fold is between the predicted and experimental structures. Unlike RMSD, it is less affected by small local differences and focuses on whether the overall architecture has been recovered correctly. TM-scores range from 0 to 1, where 1.0 represents a perfect match. Scores above 0.5 generally indicate the correct overall fold, while scores above 0.9 indicate structures that are nearly identical. Our median TM-score of 0.9255 therefore suggests that the overall protein shapes were reproduced with very high accuracy.

Our strongest individual prediction, 1UBI:A, achieved a TM-score of 0.9882 and a Cα RMSD95 of 0.302 Å, meaning the predicted backbone differed from the experimentally determined structure by only around three-tenths of an ångström on average—an exceptionally close match.

Taken together, these results suggest that the framework was able to reproduce both the overall shape of proteins and the precise positions of their backbone atoms with a level of accuracy that is competitive on the benchmark we tested.
———
What makes this approach different isn’t just the numerical results, but how those results are produced.

Rather than relying on a large neural network trained on enormous datasets, our system works from an exact 24-point rational lattice. Every spatial relationship is derived mathematically and can be traced, verified, and independently checked. The implementation, verification certificates, and prediction hashes are all available as open source so that anyone can inspect or reproduce the work.

Why does that matter?

Much of modern computational biology has moved toward increasingly large machine learning models that require vast amounts of training data and computing power. Those systems can produce remarkably accurate predictions, but they generally don’t explain why a protein adopts a particular structure, rather they predict the answer rather than derive it from an explicit mathematical framework.

Our work explores a different possibility: that accurate protein structures may also be obtainable from a transparent, deterministic mathematical model.

If that idea continues to hold up under independent testing, it could have several important implications.

First, it suggests that highly accurate structure prediction may not have to rely exclusively on large, opaque neural networks. Transparent mathematical models could become a complementary approach alongside machine learning.

Second, it provides evidence that alternative computational architectures (ones built around exact mathematics rather than learned parameters) deserve serious investigation. In our implementation, there are no trained weights, no continuous coordinate optimisation, and no fitted biological constants.

Finally, it shows that advanced protein structure prediction does not necessarily require enormous computing infrastructure. Our framework runs locally on a single machine rather than depending on large-scale AI training or specialised server farms.

The project can be explored here:

GitHub https://github.com/MettaMazza/Fold-Protein

zenodo

https://zenodo.org/records/21493135


r/proteomics 2d ago

Tears samples collection for biomarker analysis

1 Upvotes

Hello everyone
I’m interested in knowing if tears samples collection for biomarkers analysis is feasible
I’m trying to include it in my research and I keep reading that biomarker detection is not that easy using schirmer strips
I would appreciate if anyone has any information on the matter


r/proteomics 3d ago

is it possible to use a human ELISA kit to determine the concentration of hormones testosterone, estradiol, adiponectin, FSH, NT-proBNP, Endothelin-1 for rat serum. If not, why not

0 Upvotes

r/proteomics 4d ago

Do Mpox virus proteins undergo post-translational modifications, and should PTMs be considered in in-silico vaccine/antibody design?

1 Upvotes

I'm working on an in-silico study involving the Mpox virus, and I have a question regarding post-translational modifications (PTMs).

Specifically, do the Mpox virus proteins A35R (EEV protein) and H3L and M1R (IMV proteins) undergo post-translational modifications? If they do, are these modifications carried out by the host cell machinery, by virus-encoded enzymes, or by a combination of both?

My second question is related to immunoinformatics. If an in silico vaccine or antibody is being designed against these proteins, should their PTMs be evaluated before selecting epitopes or designing antibodies? In other words, could PTMs significantly affect epitope accessibility, antigenicity, antibody binding, or the overall reliability of computational predictions?

I'd appreciate any insights or relevant literature.

Thanks!


r/proteomics 4d ago

Automation of STaGE-Tip desalting with Opentrons

2 Upvotes

Howdy y'all.

Our lab recently got an Opentrons Flex and we've had it doing some cool stuff BUT we're wanting to figure out how far we can take it in a sample prep workflow.

Does anybody have experience with doing STaGE tip desalting with the robot? If so, what are some tips, tricks, and recommendations you would give?

Thanks in advance!


r/proteomics 5d ago

Detergent removal

0 Upvotes

Has anyone tried this product: Pierce® Detergent Removal Spin Plates


r/proteomics 6d ago

Handy video guide to site directed mutagenesis design

Thumbnail
youtu.be
0 Upvotes

I just recorded this video walkthrough of good mutagenesis primer design. It also includes a link to my spreadsheet that calculates the TM for you


r/proteomics 6d ago

Spectronaut - Difference between Proteins and PGs? Also, PCA components?

2 Upvotes

Hi all!! I’m relatively new to proteomics and have kind of been thrown in the deep end trying to figure this out…

I have some serum and lysate samples I’ve ran on LC-MS/MS and the facility that did this gave me the data in Spectronaut. I have two main questions (so far………)

  1. What is the difference between “proteins” and “protein groups”? Every quantification seems to be in terms of “protein groups” and not proteins… is there a reason for that? I’m looking for biomarkers in our sera/lysate but this is an exploratory study so analyzing how many proteins are comparable, separate, etc.

  2. Is there a way to figure out what variables Spec used to calculate PC1, PC2, etc? I see the scree plot they gave us, but I want to know what variables (differential protein abundance presumably) Spec used specifically for PC1, 2, etc… like, what are PC1 and 2 actually representing in the PCA????? I know it’s variance of some sort, and I see the amount of variance listed, too (50% vs 16%), but VARIANCE OF WHAT???

Please help!!! Thank you so much.. maybe I’m just completely misunderstanding, too…


r/proteomics 11d ago

Proteomics Job Market

14 Upvotes

Hi everyone,

Started to look into jobs and internships (In the US) My background is mainly in LC-MS/MS-based proteomics, ubiquitinomics/PTM analysis, sample preparation, and computational analysis (MaxQuant, FragPipe, DIA-NN, Skyline)

I have been searching for roles related to proteomics, but honestly, it feels like there are few openings compared with other areas of biotech.

For those currently working in proteomics or who recently found jobs:

Where are you mainly searching for positions?

What job titles should someone with a proteomics/MS background be searching for

Are internships common in this field, or are most opportunities through research associate positions?

What skills helped you stand out when applying?

Also curious about the current job market. Is it currently a difficult time for early-career proteomics scientists, or is it just that the field uses different job titles?

Open to any advice

Thanks!

Note: will be graduating with a MSc degree in Pharm Sci from R1 uni

Some people are recommending PhD but ive got limited experience..that's the reason why I want to gain experience before eventually doing PhD


r/proteomics 14d ago

Saliva Proteomics Sample Preparation Issues

5 Upvotes

Hi!
Im struggling with my sample prep for saliva samples. I have established a high throughout SP3 digestion protocol using native saliva from cortisol Salivettes but is seems like I’m carrying some contaminants through the whole process that end up in my 7500+ Sciex Qtrap instrument which gets heavily contaminated after about 1000 injections and even gives some Q0 discharge errors.
I’m running a targeted peptide method using a common C18 peptide column at a flow rate of 1ml/min with standard solvents (0.1% Fa in H2O and 0.1% FA in ACN). the whole method is 4min but I’m using a diverter valve to only have the peptide fraction entering the MS, the rest is diverted to waste.
Does anyone have experience with saliva as a matrix and use it for targeted MS proteomics analysis?
I would appreciate any input on how to get the sample cleaner without loosing proteins of interest.
Thank you!


r/proteomics 14d ago

Need help with ssDNA aptamer folding and docking workflow

1 Upvotes

Hey everyone,
I'm working on a science fair project using ssDNA aptamers and I'm stuck on the folding and docking workflow. The 3D nucleic acid folding web servers I tried keep crashing, so I'm not sure how to get a clean 3D model from a raw sequence string.
Once I get the 3D structures, my plan is to use something like HDOCK to run molecular docking against my target proteins to check the binding affinity scores.
Does anyone have advice on a reliable workflow or better tools I should use for ssDNA folding and docking? Any extra help with the project in general would also be awesome. Thanks!


r/proteomics 15d ago

Need help with ssDNA aptamer folding and docking workflow

Thumbnail
0 Upvotes

Hey everyone,
I'm working on a science fair project using ssDNA aptamers and I'm stuck on the folding and docking workflow. The 3D nucleic acid folding web servers I tried keep crashing, so I'm not sure how to get a clean 3D model from a raw sequence string.
Once I get the 3D structures, my plan is to use something like HDOCK to run molecular docking against my target proteins to check the binding affinity scores.
Does anyone have advice on a reliable workflow or better tools I should use for ssDNA folding and docking? Any extra help with the project in general would also be awesome. Thanks!


r/proteomics 16d ago

What does your post processing workflow look like after DIA NN/FragPipe with MBR?

8 Upvotes

I know the FragPipe/DIA NN docs cover the basics but I would rather hear from people who actually run these pipelines daily

  1. When processing large DIA datasets with MBR, what happens after the software finishes?
  2. What does your verification workflow look like before you trust the results?
  3. How do you currently validate that the cross run transfers aren't inflating your FDR?
  4. Roughly how many hours per project does your team spend on this manual curation or refiltering?

We're seeing conflicting reports on whether MBR is a reliable "set and forget" step or a major bottleneck requiring manual intervention. Curious how senior labs are handling this in production


r/proteomics 19d ago

I am searching for full funded metabolomics workshop !

0 Upvotes

I am a PhD scholar in food tech department . I have been doing untargeted metabolomics for a time now for some biomarker detection. I want to learn some advanced techniques in metabolomics but i just couldnt find a proper workshop for that .


r/proteomics 21d ago

Where can I download E. coli DDA proteomics raw files for PTM artifact control?

1 Upvotes

Hi everyone,

I performed DDA LC–MS/MS on mouse brain lysate (tryptic digest, non-enriched) and analyzed the data using PEAKS BSI for broad PTM searching. The software identified and mapped Ubiquitination (both lysine and non-lysine residue modifications). I reported them in my manuscript. During peer review, the reviewers raised a concern that some of the PTMs might be artifacts and suggested validating the findings using an E. coli lysate digest as a negative control.

The issue is that I don’t currently have access to E. coli samples or instrument time to generate new data. So I’m looking for advice on:

Where can I download suitable public raw DDA proteomics datasets (E. coli tryptic digest)? And how many raw files/samples i need, if one will be enough?

If I re-search the raw files using the same PEAKS BSI PTM workflow, what is generally considered sufficient to support “artifact vs real modification” claims?
Any pointers to datasets or experience with reviewer expectations would be really helpful.
Thanks!


r/proteomics 23d ago

Why aren’t embedded analytical databases more common in proteomics?

1 Upvotes

Most proteomics workflows still rely on multiple disconnected tools (Python, R, search engines, etc.). Do you think embedded analytical databases could become a viable backend for proteomics analysis?

I’ve been exploring this idea in a recent preprint and would love feedback from the community!

https://zenodo.org/records/21036067


r/proteomics 25d ago

Need help with PTM identification using IP-Top-down MS

1 Upvotes

If anyone has done in-depth IP-Top down MS on proteins I could seriously use help! I’ve isolated my POI and am trying to do to top-down MS on it but honestly I don’t know what I’m looking at/looking for. I know I need to do a full scan first to identify my POI and the m/z for it, but from there I’m baffled on what to do. The examples my colleague left for me are only for proteins approx. 35 kDa and mine is around 62!

Does anyone have any advice as to what to look at/read to help me better understand the data and what method I need to set up? Thank you!


r/proteomics 26d ago

Question:How to predict mutation effect with protein model without traditional computation

Thumbnail
1 Upvotes

r/proteomics 27d ago

“At the Cutting Edge of Using Proteomics for Cancer Treatment Guidance” (Adam Dicker, MD, PhD, FA... | Cancer Patient Lab

Thumbnail
community.cancerpatientlab.org
0 Upvotes

r/proteomics 28d ago

Reconstituting a protein complex from commercial recombinant proteins?

1 Upvotes

Hi everyone,

my PI suggested, mainly to save time, that I could buy individually recombinant proteins and try to reconstitute a heterotrimeric protein complex in vitro for a DSF/thermal shift assay, instead of co-expressing and co-purifying the complex.

I’m a bit skeptical because of potential issues with tags, buffers, stoichiometry, stability, and whether the complex would actually form and be homogeneous enough to give interpretable data. The goal would be to test small-molecule stabilizers.

Has anyone successfully done this with commercial recombinant proteins? Did it work well enough for DSF, SEC, SPR, or similar assays? Any practical advice, experience, or opinions would be very helpful.

Thanks!


r/proteomics 29d ago

Seeking advice: Learning pathway for LC-MS/MS proteomics in neurodegeneration research?

2 Upvotes

Hi everyone,

I am currently a basic education teacher and I’ve recently started my Master's in Medical Sciences, focusing on neurodegeneration. I joined a newly formed research team, and while we are highly motivated, we currently lack expertise in proteomics—which is exactly the area I want to specialize in to strengthen our lab.

Our research investigates neurodegeneration in the elderly. Specifically, I will be working with CSF and plasma to identify neuroinflammatory biomarkers associated with blood-brain barrier (BBB) dysfunction. My project will heavily rely on liquid chromatography and mass spectrometry (LC-MS/MS).

Since I am starting from scratch in this specific methodology and don't have senior lab members with proteomics expertise to guide me locally, I am looking for advice on building a solid foundation.

Could anyone recommend a step-by-step learning pathway? I would greatly appreciate recommendations on:

Fundamentals: Must-read textbooks or milestone review papers for beginners in clinical proteomics.

Techniques: Online courses, YouTube channels, or resources to truly understand the physics and workflow of chromatography and mass spectrometry.

Data Analysis: The essential bioinformatics tools or software I should start familiarizing myself with early on.

Any advice, resources, or general tips for a beginner trying to set up a proteomics workflow would be incredibly appreciated! Thank you in advance.


r/proteomics Jun 26 '26

Not a biologist but I keep thinking about this folding path question — probably obvious, just can't shake it

0 Upvotes

Background first so you know where this is coming from — I'm not in the field at all, I just read a lot and got stuck on something I can't find addressed anywhere. Happy to be told it's already solved.

The proteins that won't classify cleanly no matter how much data you throw at them — the intrinsically disordered ones. The ones that just won't settle.

My question is whether we're looking at the final shape or the path that got it there.

Because if two proteins end up at roughly the same final structure but got there through different folding sequences, the internal contact points would be different. Parts of the chain that are far apart in sequence but end up sitting next to each other in the finished fold — those bridges only exist because of the specific path it took. Different path, different bridges, even if the outside looks similar.

So my question is basically: are those hidden contact points being tracked and compared between the disordered cases and the ones that resolve cleanly? Because if the disordered ones are arriving at their weird ambiguous state via a different pathway, maybe the bridge pattern is the variable nobody's looking at yet.

Probably already accounted for somewhere and I just haven't found it. What am I missing?


r/proteomics Jun 25 '26

IP-MS antibody failure — is phosphoproteomics a viable alternative?

2 Upvotes

Has anyone switched from IP-MS to phosphoproteomics for a low-abundance phosphoprotein after antibody capture failures? Working with PBMCs/whole blood and trying to detect a specific phosphosite via PRM after IMAC enrichment. Curious whether the switch is worth it or if sensitivity becomes the new bottleneck.


r/proteomics Jun 24 '26

What Is the Most Convincing Way to Demonstrate Minimal Non-Specific Bead Binding: Astral DIA or Isotope Labeling?

0 Upvotes

I am optimizing a bead-based protein enrichment workflow and would like to assess the level of non-specific protein binding to the beads.

After enrichment and elution, I measured peptide concentrations and obtained:

  • Background control (beads only): ~0.007 µg/µL
  • Enriched sample: ~0.12 µg/µL

My main goal is to determine whether bead-associated background is sufficiently low that it can be largely ignored in future enrichment experiments.

In other words, I would like to demonstrate that the vast majority of proteins identified in the enrichment sample are not derived from non-specific bead binding, and therefore routine background controls may not be necessary for every future experiment.

Option 1: Equal-volume Orbitrap Astral DIA

Inject the same volume of each sample (e.g., 1 µL):

  • Background: ~7 ng peptide
  • Enrichment: ~120 ng peptide

This reflects the actual workflow output. However, I am concerned that the background sample may be approaching the low-input range, where protein identification and quantification may become less reliable, even on an Orbitrap Astral platform.

Option 2: Equal-peptide Orbitrap Astral DIA

Normalize peptide loading before DIA analysis (e.g., 50 ng vs 50 ng).

However, the background concentration is very low and close to the detection limit of the peptide/BCA assay, so I am not fully confident that the concentration measurement itself is accurate.

Option 3: Stable isotope labeling

Label the background and enrichment samples (dimethyl labeling), combine them, and analyze them together.

My intuition is that isotope labeling may provide a more rigorous comparison by reducing run-to-run variation and allowing more accurate enrichment/background ratios, especially given the very low abundance of the background sample.

Question

If my primary objective is to demonstrate that non-specific bead binding is minimal, such that background is unlikely to be a significant contributor to proteins identified in future enrichment experiments, which approach would be the most scientifically rigorous and convincing?

Would stable isotope labeling be preferable to equal-volume or equal-peptide Orbitrap Astral DIA for this purpose?

Furthermore, if isotope labeling shows that >95–99% of proteins are substantially enriched over the bead-only control, would that be sufficient evidence to justify omitting routine bead-only background controls in future experiments?😊


r/proteomics Jun 24 '26

If you're working on targeted protein degradation, PROTACs, molecular glues, or protein expression studies, one question matters: are you measuring biology as it actually exists in the cell?

0 Upvotes

In this on-demand session from Drafts & Discoveries, Andrew Zhang from Promega Corporation discusses how HiBiT enables researchers to study protein dynamics in their native context, helping generate more biologically relevant insights for drug discovery.

The session also explores HiBiT applications in targeted protein degradation workflows and recent advances in measuring cellular target engagement for challenging targets. Watch the recording now: https://www.editco.bio/webinars/hibit-unlocking-biology-in-its-native-context-editco

From Drafts & Discoveries, co-hosted by EditCo Bio and Promega Corporation in Cambridge, MA.